A serum immunofixation test looks for an abnormal monoclonal immunoglobulin in blood and identifies what type it is. The result can help confirm that a suspicious protein seen on serum protein electrophoresis is truly monoclonal, and it can classify the protein by heavy chain—such as IgG, IgA, or IgM—and light chain, kappa or lambda. That information is important when evaluating multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell or B-cell disorders. Immunofixation is very sensitive for small monoclonal proteins, but it does not by itself diagnose cancer or accurately measure the amount of an M protein. Doctors interpret it together with serum protein electrophoresis, serum free light chains, quantitative immunoglobulins, blood counts, kidney function, calcium, imaging, and sometimes bone marrow testing. A positive result therefore answers an important laboratory question—whether a monoclonal protein is present and what type it is—while the clinical meaning depends on the full pattern.
- A positive serum immunofixation result means a monoclonal immunoglobulin or light chain was detected, but it does not by itself prove multiple myeloma.
- Immunofixation identifies the M-protein type, such as IgG-kappa, IgA-lambda, IgM-kappa, or a free light chain pattern.
- A negative result makes a detectable serum monoclonal protein less likely, although very low-level, nonsecretory, or urine-predominant disease can still require other tests.
- No fasting is usually required; the test is performed on a routine blood sample, and preparation is generally minimal.
- Results should be interpreted with SPEP and serum free light chains, because immunofixation is excellent for identification but is not the main method for quantifying an M spike.
Table of Contents
- What Serum Immunofixation Measures
- Why the Test Is Ordered
- How to Read a Serum Immunofixation Result
- Immunofixation vs SPEP and Free Light Chains
- What Positive Patterns Can Mean
- Monitoring Treatment and Common Pitfalls
- What Happens After an Abnormal Result
What Serum Immunofixation Measures
Serum immunofixation electrophoresis, often shortened to serum IFE or SIFE, detects and characterizes immunoglobulins made by a single clone of plasma cells or B cells. Normal blood contains a broad mixture of antibodies produced by many different cell clones. On immunofixation, that normal mixture usually appears as a diffuse pattern. A monoclonal protein produces a narrow, discrete band because many identical antibody molecules are present.
An immunoglobulin has two heavy chains and two light chains. Serum IFE commonly uses antisera that react with the major heavy-chain classes—IgG, IgA, and IgM—and with kappa and lambda light chains. The laboratory compares the bands across these lanes to determine whether the abnormal protein has a matching heavy- and light-chain identity. For example, a band in the IgG lane that aligns with a band in the kappa lane is reported as an IgG-kappa monoclonal protein.
Some disorders produce only free light chains rather than a complete immunoglobulin. In that situation, the pattern may show a restricted kappa or lambda band without a corresponding heavy-chain band. This is one reason a serum free light chain test is commonly used alongside immunofixation.
Serum IFE is primarily a qualitative identification test. It can answer questions such as:
- Is a monoclonal protein detectable?
- Which heavy chain is involved?
- Which light chain is involved?
- Is there more than one distinct monoclonal component?
- Is a small suspicious band on electrophoresis likely to be monoclonal?
It is not designed to provide a precise M-protein concentration. That role usually belongs to serum protein electrophoresis or, in selected situations, other quantitative methods.
Why the Test Is Ordered
Doctors order serum immunofixation when symptoms, routine laboratory abnormalities, or another protein test raises concern for a monoclonal gammopathy. It is also used to establish a baseline after diagnosis and to confirm deep treatment responses in some plasma cell disorders.
Common reasons for testing include unexplained anemia, kidney dysfunction, high calcium, bone pain, fractures, recurrent infections, neuropathy, elevated total protein, a low albumin-to-globulin ratio, or a suspicious band on electrophoresis. Serum IFE may also be ordered when clinicians are evaluating unexplained proteinuria, cardiomyopathy, nephrotic syndrome, or other findings that can occur in AL amyloidosis or monoclonal gammopathy of renal significance.
A typical initial monoclonal-protein evaluation combines several complementary tests rather than relying on immunofixation alone. A serum protein electrophoresis test screens for and quantifies many M proteins, while serum IFE identifies the immunoglobulin type and free light chains increase sensitivity for light-chain disease. Quantitative IgG, IgA, and IgM levels may provide additional context.
Serum IFE may be especially useful when:
- SPEP shows a faint or questionable restriction.
- The M protein is too small to measure reliably on SPEP.
- An abnormal free light chain ratio suggests a clonal process.
- The suspected protein migrates in the beta region, where other serum proteins can obscure it.
- A clinician needs to document the original M-protein type before treatment.
- A patient is being assessed for complete response and a previously known band has become very small.
No special diet or fasting is usually needed. A routine venous blood sample is collected, allowed to clot, and the serum is analyzed. The ordering clinician should know about the patient’s diagnosis and current therapy because monoclonal antibody drugs can affect interpretation.
How to Read a Serum Immunofixation Result
The exact wording varies by laboratory, but most reports describe whether a monoclonal protein is present and, if present, its heavy- and light-chain type. Some laboratories use terms such as “monoclonal band,” “restricted band,” “paraprotein,” or “M protein.”
| Report wording or pattern | Usual interpretation | Typical next context to review |
|---|---|---|
| No monoclonal protein detected | No serum monoclonal band is visible at the assay’s detection level | SPEP, free light chains, urine studies, and clinical suspicion |
| IgG-kappa monoclonal protein | A clonal IgG immunoglobulin with kappa light chain is present | M-protein quantity, blood counts, calcium, kidney function, marrow/imaging if indicated |
| IgA-lambda monoclonal protein | A clonal IgA immunoglobulin with lambda light chain is present | Consider beta-region migration and correlate with SPEP quantification |
| Monoclonal free kappa or lambda light chain | A restricted light chain is present without a matching heavy-chain band | Serum free light chain concentration/ratio and urine evaluation |
| Oligoclonal or multiple small bands | Several restricted bands may reflect immune recovery, treatment effects, or more than one clone | Prior baseline pattern, transplant history, therapy, and serial trends |
A positive result does not have a universal “high” or “low” value because IFE is not primarily numeric. The clinical significance depends on the disease context and the amount of monoclonal protein measured by other tests. A tiny band can occur in MGUS, which is common with aging, but a small M protein can also be clinically important in AL amyloidosis or kidney disease. Conversely, a larger M protein does not automatically establish symptomatic myeloma without other diagnostic criteria.
A negative serum IFE is reassuring but not absolute. A monoclonal protein may be below the assay’s detection limit, produced mainly in urine, or absent in nonsecretory disease. If clinical suspicion remains high, clinicians may add free light chain testing, urine electrophoresis and urine immunofixation, bone marrow studies, imaging, or more sensitive blood-based methods where available.
Immunofixation vs SPEP and Free Light Chains
These tests overlap, but they answer different questions. The most useful interpretation comes from the pattern across tests rather than from treating one result as definitive.
SPEP asks, “Is there an abnormal protein peak, and how much is there?” It separates serum proteins into fractions and often allows an M spike to be measured in g/dL or g/L. It is less sensitive than immunofixation for very small monoclonal proteins.
Serum immunofixation asks, “What type of monoclonal protein is this?” It uses antibodies to identify heavy- and light-chain classes and can detect bands that are too small or poorly positioned for reliable SPEP quantification.
Serum free light chain testing asks, “Are free kappa or lambda light chains disproportionately increased?” It provides numeric kappa, lambda, and ratio results and is particularly useful for light-chain myeloma, AL amyloidosis, and other low-secretory disorders.
The multiple myeloma test panel therefore commonly includes all three because a monoclonal gammopathy can present in more than one way.
The tests also have different limits. SPEP can miss a small band. Immunofixation can detect a band but cannot reliably quantify it. Free light chain values can be distorted by reduced kidney clearance and may not identify an intact immunoglobulin as directly as IFE. Using the same laboratory and assay platform over time can also improve trend interpretation because electrophoresis and free light chain methods vary between laboratories.
Mass spectrometry is increasingly being studied and adopted for monoclonal protein detection. It can be more sensitive than conventional electrophoresis and may distinguish a patient’s M protein from some therapeutic monoclonal antibodies. Even so, availability and clinical workflows vary, and IFE remains a widely used routine test.
What Positive Patterns Can Mean
A monoclonal protein is a marker of a clonal B-cell or plasma-cell population, not a diagnosis by itself. The same laboratory pattern can occur across a spectrum from an asymptomatic precursor condition to a malignancy that needs treatment.
MGUS is one common explanation. In MGUS, a monoclonal protein is present without the myeloma-defining features or other evidence of a related malignancy. Most people with MGUS do not progress quickly, but the condition is followed because a small annual risk of progression persists over time. Risk assessment depends on factors such as M-protein amount and type, free light chain ratio, and the specific clinical setting.
Smoldering multiple myeloma involves a larger clonal plasma-cell burden than MGUS but no myeloma-defining event that requires treatment. Monitoring is closer because progression risk is higher, especially in patients with recognized high-risk features.
Active multiple myeloma requires more than a positive IFE. Diagnosis integrates clonal plasma cells or plasmacytoma with myeloma-defining events, which can include organ damage such as hypercalcemia, renal impairment, anemia, or bone lesions, as well as specific validated biomarkers. For this reason, a positive IFE is one component of a broader diagnostic workup.
Waldenström macroglobulinemia often produces an IgM monoclonal protein. An IgM band on IFE does not establish Waldenström macroglobulinemia on its own; clinicians correlate it with symptoms, marrow findings, and molecular features.
AL amyloidosis and monoclonal gammopathy of clinical significance may involve a very small clone but substantial organ effects. A faint band should not be dismissed if there are compatible kidney, heart, nerve, or other organ findings.
Biclonal or oligoclonal patterns require added context. Two distinct monoclonal proteins can occur, while several small bands after successful myeloma treatment or stem cell transplantation may reflect immune reconstitution rather than the original malignant clone. Comparing the current band with the pretreatment isotype and migration position can be very helpful.
Monitoring Treatment and Common Pitfalls
Serum immunofixation can help assess response because the disappearance of a previously documented monoclonal protein is part of conventional response assessment in secretory myeloma. However, IFE should not be used as a stand-alone measure of tumor burden. Clinicians usually follow the M-protein concentration on SPEP when it is measurable, involved free light chains when appropriate, symptoms, organ function, and deeper response tests such as bone marrow MRD when indicated.
A major modern pitfall is therapeutic monoclonal antibody interference. Drugs used in plasma cell disorders can themselves appear as monoclonal immunoglobulin bands. Daratumumab and isatuximab, for example, are IgG-kappa antibodies and can mimic a residual IgG-kappa M protein. Laboratories may use drug-specific reflex assays or newer mass-spectrometry methods to separate treatment-related signal from the patient’s original protein. Medication history therefore matters when an unexpected faint IgG-kappa band appears during therapy.
Other interpretation issues include:
- Low-level bands near the detection limit. These may be real but require correlation with serial tests and the original clone.
- Beta-region migration. IgA and some other monoclonal proteins may migrate outside the classic gamma region, complicating SPEP measurement while remaining identifiable by IFE.
- Kidney disease. Renal impairment can markedly raise serum free light chains, so an abnormal free light chain level is not interchangeable with a positive IFE.
- Polyclonal hypergammaglobulinemia. Infection, inflammation, autoimmune disease, and liver disease can increase many immunoglobulins at once, creating a broad pattern rather than a discrete monoclonal band.
- Oligoclonal reconstitution. New small bands after transplant or effective therapy can differ from the original M protein and may not represent relapse.
When serial monitoring matters, testing at the same laboratory can reduce confusion from platform differences. The clinician should also compare the current isotype with the one documented at diagnosis rather than reacting to the word “positive” alone.
What Happens After an Abnormal Result
The next step depends on why the test was ordered and whether the monoclonal protein is new, known, or changing. A new positive result usually leads to a structured evaluation rather than an immediate cancer diagnosis.
Common follow-up tests include a complete blood count, creatinine or estimated glomerular filtration rate, calcium, albumin, total protein, quantitative immunoglobulins, SPEP with M-protein measurement, and serum free light chains. Urine protein studies may be added when light-chain disease, AL amyloidosis, renal involvement, or measurable urinary monoclonal protein is a concern. The clinician may then decide whether bone marrow biopsy and imaging are needed.
Urgency depends more on symptoms and organ findings than on the IFE band alone. Prompt medical assessment is appropriate for new severe bone pain or suspected fracture, marked weakness, confusion, dehydration, worsening kidney function, shortness of breath, significant anemia, or symptoms of hypercalcemia. A stable small monoclonal protein in an otherwise well person is commonly evaluated on a non-emergency basis.
If a monoclonal gammopathy is diagnosed but treatment is not required, follow-up intervals are individualized. Low-risk MGUS may be monitored less frequently after an initial reassessment, while higher-risk MGUS or smoldering myeloma needs closer surveillance. Active myeloma and related disorders are monitored according to treatment response and disease characteristics.
The most useful questions to ask when reviewing a report are practical ones: What is the exact isotype? Is the same clone visible on SPEP? How much M protein is present? Is the free light chain ratio abnormal? Are blood counts, calcium, or kidney function changing? Is this the same band that was present at diagnosis? Those answers turn a technically “positive” immunofixation result into clinically useful information.
For long-term follow-up, keeping a copy of the original immunofixation pattern can be surprisingly useful. The original isotype and migration position help the laboratory and clinician decide whether a faint band years later represents the same clone, a treatment antibody, or a new oligoclonal immune-recovery pattern. This is especially helpful after stem cell transplantation or highly effective combination therapy, when several small bands may appear despite deep control of the original myeloma.
References
- Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies 2023 (Consensus)
- A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing 2023 (Review)
- Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review 2025 (Review)
- Multiple Myeloma: A Structured and Multidisciplinary Approach to Diagnosis 2026 (Review)
- Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents 2024
- Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma 2022
Disclaimer
Serum immunofixation results must be interpreted with the patient’s symptoms, other monoclonal-protein tests, kidney function, and clinical history. A positive monoclonal band does not by itself diagnose multiple myeloma, and a negative result does not exclude every plasma cell disorder. Discuss unexpected or changing results with the clinician managing the workup.
